11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Reed-Sternberg cells in Hodgkin's lymphoma present features of cellular senescence

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Hodgkin's Lymphoma (HL) is one of the most prevailing malignancies in young adults. Reed–Sternberg (RS) cells in HL have distinctive large cell morphology, are characteristic of the disease and their presence is essential for diagnosis. Enlarged cells are one of the hallmarks of senescence, but whether RS cells are senescent has not been previously investigated. Here we show that RS cells have characteristics of senescent cells; RS cells in HL biopsies specifically express the senescence markers and cell cycle inhibitors p21 Cip1 and p16 INK4a and are negative for the proliferation marker Ki-67, suggesting that these cells have ceased to proliferate. Moreover, the RS-like cells in HL lines, stained specifically for senescence-associated β-galactosidase (SA- β-gal). Oxidative stress promoted senescence in these cells as demonstrated by their staining for p21 Cip1, p16 INK4a, p53 and γH2AX. Senescent cells produce copious amounts of inflammatory cytokines termed ‘senescence-associated secretory phenotype' (SASP), primarily regulated by Nuclear Factor κB (NF- κB). Indeed, we show that NF- κB activity and NF- κB-dependent cytokines production (e.g., IL-6, TNF- α, GM-CSF) were elevated in RS-like cells. Furthermore, NF- κB inhibitors, JSH-23 and curcumin reduced IL-6 secretion from RS-like cells. Thus, defining RS cells as senescent offers new insights on the origin of the proinflammatory microenvironment in HL.

          Related collections

          Most cited references27

          • Record: found
          • Abstract: found
          • Article: not found

          Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.

          Oncogenic ras can transform most immortal rodent cells to a tumorigenic state. However, transformation of primary cells by ras requires either a cooperating oncogene or the inactivation of tumor suppressors such as p53 or p16. Here we show that expression of oncogenic ras in primary human or rodent cells results in a permanent G1 arrest. The arrest induced by ras is accompanied by accumulation of p53 and p16, and is phenotypically indistinguishable from cellular senescence. Inactivation of either p53 or p16 prevents ras-induced arrest in rodent cells, and E1A achieves a similar effect in human cells. These observations suggest that the onset of cellular senescence does not simply reflect the accumulation of cell divisions, but can be prematurely activated in response to an oncogenic stimulus. Negation of ras-induced senescence may be relevant during multistep tumorigenesis.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Forging a signature of in vivo senescence.

            'Cellular senescence', a term originally defining the characteristics of cultured cells that exceed their replicative limit, has been broadened to describe durable states of proliferative arrest induced by disparate stress factors. Proposed relationships between cellular senescence, tumour suppression, loss of tissue regenerative capacity and ageing suffer from lack of uniform definition and consistently applied criteria. Here, we highlight caveats in interpreting the importance of suboptimal senescence-associated biomarkers, expressed either alone or in combination. We advocate that more-specific descriptors be substituted for the now broadly applied umbrella term 'senescence' in defining the suite of diverse physiological responses to cellular stress.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Control of the senescence-associated secretory phenotype by NF-κB promotes senescence and enhances chemosensitivity.

              Cellular senescence acts as a potent barrier to tumorigenesis and contributes to the anti-tumor activity of certain chemotherapeutic agents. Senescent cells undergo a stable cell cycle arrest controlled by RB and p53 and, in addition, display a senescence-associated secretory phenotype (SASP) involving the production of factors that reinforce the senescence arrest, alter the microenvironment, and trigger immune surveillance of the senescent cells. Through a proteomics analysis of senescent chromatin, we identified the nuclear factor-κB (NF-κB) subunit p65 as a major transcription factor that accumulates on chromatin of senescent cells. We found that NF-κB acts as a master regulator of the SASP, influencing the expression of more genes than RB and p53 combined. In cultured fibroblasts, NF-κB suppression causes escape from immune recognition by natural killer (NK) cells and cooperates with p53 inactivation to bypass senescence. In a mouse lymphoma model, NF-κB inhibition bypasses treatment-induced senescence, producing drug resistance, early relapse, and reduced survival. Our results demonstrate that NF-κB controls both cell-autonomous and non-cell-autonomous aspects of the senescence program and identify a tumor-suppressive function of NF-κB that contributes to the outcome of cancer therapy.
                Bookmark

                Author and article information

                Journal
                Cell Death Dis
                Cell Death Dis
                Cell Death & Disease
                Nature Publishing Group
                2041-4889
                November 2016
                10 November 2016
                1 November 2016
                : 7
                : 11
                : e2457
                Affiliations
                [1 ]The Shraga Segal Department of Microbiology Immunology and Genetics, Faculty of Health Sciences, Ben Gurion University of The Negev , Beer Sheva 84105, Israel
                [2 ]Department of Oncology, Soroka University Medical Center , Beer Sheva 84105, Israel
                [3 ]Flow Cytometry Unit, Hematology Laboratory and Institute of Hematology , Beer Sheva 84105, Israel
                [4 ]Department of Pathology, Soroka University Medical Center , Beer Sheva 84105, Israel
                [5 ]Blood Cell Development and Function Program, Fox Chase Cancer Center , Philadelphia, PA 19111, USA
                Author notes
                [* ]The Shraga Segal Department of Microbiology Immunology and Genetics, Faculty of Health Sciences, Ben Gurion University of The Negev , Beer Sheva 84105, Israel. Tel: 972 8 6477294; Fax: 972 8 6477626; E-mail: jacob@ 123456bgu.ac.il
                Article
                cddis2016185
                10.1038/cddis.2016.185
                5287295
                27831553
                f2cea409-20de-4b6c-9392-1617e5681c00
                Copyright © 2016 The Author(s)

                Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

                History
                : 01 October 2015
                : 06 June 2016
                : 07 June 2016
                Categories
                Original Article

                Cell biology
                Cell biology

                Comments

                Comment on this article